Purpose
To evaluate real-world utility of the ForeseeHome monitoring device for the detection of conversion from intermediate age-related macular degeneration (iAMD) to neovascular AMD (nAMD) and compare with results published by the HOME study.
Design
Retrospective analysis of electronic health records.
Subjects
Eyes prescribed use of the ForeseeHome device across 4 retinal practices in the USA.
Methods
Usage information was collected from the online ForeseeHome portal for all eyes prescribed. For a pre-determined subset of eyes, additional clinical information was collected through chart review and analyzed for clinical utility.
Main Outcome Measures
Outcome measures include frequency and length of use, number of eyes that used the device, established baseline and converted to nAMD, and number of alerts.
Results
775 eyes of 448 patients were prescribed use of the ForeseeHome device. 649 eyes (83.7%) used the device at least once; among this population, 478 (73.7%) established baseline. Patients who established baseline were significantly younger than those who did not establish baseline (p<0.001). Among eyes that established baseline, 126 (26.4%) had an overall inadequate frequency of use (≥2 tests per week), and 250 (52.3%) did not use the device as frequently as instructed by the manufacturer (≥3 tests per week); 112 (24.7%) discontinued use within one year. Over a mean of 20.35 months, 106 patients had 152 alerts, indicating possible conversions to nAMD. Out of the 136 eyes that established baseline among 211 eyes prescribed the device at one clinical site, 52 alerts were recorded, 3 (6.8%) correctly identified conversion to nAMD and 47 (93.2%) represented false-positive alerts.
Conclusions
Compared to the prospective HOME study, utility of the ForeseeHome device in the current analysis of real-world clinical-practice application was limited. A meaningful proportion of eyes never used the device or could not establish baseline. Overall frequency of use was low and continuous usage of the device decreased over time. There is a need for improvement in home monitoring technology for eyes with iAMD at risk of conversion to nAMD.